Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate)
Open Access
- 30 March 2021
- journal article
- research article
- Published by Springer Nature in CNS Drugs
- Vol. 35 (5) , 567-574
Abstract
Background Tecfidera® (dimethyl fumarate [DMF]) is an approved product for the treatment of relapsing forms of multiple sclerosis. Monomethyl fumarate (MMF) is the only active metabolite of DMF and is responsible for its therapeutic efficacy. Objective The objective of this study was to determine whether two Bafiertam™ capsules each containing 95 mg of MMF is bioequivalent to one Tecfidera® capsule containing 240 mg of DMF, a prodrug of MMF. Methods This was a single-dose, open-label, randomized, two-way crossover study evaluating two treatments over two periods with a washout interval between treatments. Fifty healthy subjects were randomized to receive a single dose of the test drug MMF 190 mg as 2 × 95 mg delayed-release capsules or the reference drug DMF 240 mg as a 1 × 240-mg delayed-release capsule. Blood samples were obtained prior to dosing and at prespecified time points through 24 h post-dose to determine plasma concentrations of MMF. The pharmacokinetic parameters of MMF were calculated including maximum observed concentration, time to reach maximum observed concentration, apparent half-life of the drug in plasma, AUC0–t which is the area under the plasma concentration–time curve (AUC) from time zero (dosing time) to the last time point, t, with measurable analyte concentration, and AUC0–inf, which is AUC0–t plus the extrapolated AUC from time t to infinity. Results The geometric least-squares mean ratios (90% confidence interval) of the test drug MMF vs the reference drug DMF were 96.80% (92.18–101.64), 96.35% (91.81–101.12), and 104.84% (95.54–115.05) for AUC0–t, AUC0–inf, and maximum observed concentration, respectively. Two capsules of Bafiertam™ was safe and generally well tolerated. The most common adverse event for both products was flushing, 60% and 51%, for Bafiertam™ and Tecfidera®, respectively. Conclusions Based on the statistical analysis results of the pharmacokinetic parameters of MMF, a single oral dose of two Bafiertam™ DR 95 mg capsules is bioequivalent to a single oral dose of one Tecfidera® DR 240 mg capsule. Clinical Trial Registration This study was retrospectively registered with ClinicalTrials.gov (NCT04570670) on 30 September, 2020.Keywords
This publication has 13 references indexed in Scilit:
- Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarateMultiple Sclerosis and Related Disorders, 2020
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension studyMultiple Sclerosis Journal, 2016
- Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE)International Journal of MS Care, 2016
- Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNSActa Neuropathologica, 2015
- Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAEJournal of Clinical Investigation, 2014
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple SclerosisNew England Journal of Medicine, 2012
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisNew England Journal of Medicine, 2012
- The cause of the Chinese sofa/chair dermatitis epidemic is likely to be contact allergy to dimethylfumarate, a novel potent contact sensitizerBritish Journal of Dermatology, 2008
- Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid estersBiopharmaceutics & Drug Disposition, 2003
- Sample size determination for bioequivalence assessment using a multiplicative modelJournal of Pharmacokinetics and Biopharmaceutics, 1992